 |
|
|
| |
Interim Analysis of an Interferon (IFN)- and Ribavirin (RBV)-Free Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 in Treatment-Naive, Hepatitis C Virus Genotype 1-Infected Patients
|
| |
| |
Reported by Jules Levin
IDSA Oct 2-6 2013 San Francisco, CA
Gregory T. Everson*1, Karen D. Sims2, Maribel Rodriguez-Torres3, Christophe Hezode4,
Eric Lawitz5, Marc Bourliere6, Veronique Loustaud-Ratti7, Vinod Rustgi8, Howard Schwartz9, Harvey Tatum10, Patrick Marcellin11, Stanislas Pol12, Paul J. Thuluvath13, Timothy Eley2, Xiaodong Wang2, Shu-Pang Huang14, Fiona McPhee15, Megan Wind-Rotolo14, Ellen Chung2, Claudio Pasquinelli2, Dennis M. Grasela2, David F. Gardiner2
1University of Colorado Denver, Aurora, CO, USA; 2Bristol-Myers Squibb, Hopewell, NJ, USA; 3Fundacion de Investigacion, San Juan, Puerto Rico; 4CHU Henri Mondor, Service d'Hepato-Gastroenterologie, Creteil, France; 5Alamo Medical Research, San Antonio, TX, USA; 6Hôpital Saint Joseph, Service d'Hepato-Gastroenterologie, Marseille, France; 7University Hospital of Limoges, Limoges, France; 8Metropolitan Research, Arlington, VA, USA; 9Miami Research Associates, South Miami, FL, USA; 10Options Health Research, Tulsa, OK, USA; 11Hôpital Beaujon, Clichy, France; 12Universite Paris Descartes, INSERM U1610 and Liver Unit, Hôpital Cochin, Paris, France; 13Mercy Medical Center, Baltimore, MD, USA; 14Bristol-Myers Squibb, Princeton, NJ, USA; 15Bristol-Myers Squibb, Wallingford, CT, USA
|
| |
|
|
|
|
|
